Cargando…
Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients
BACKGROUND: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. OBJECTIVES: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. PATIENTS AND METHODS: Thirty-one naïve patients with chronic hepat...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kowsar
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269061/ https://www.ncbi.nlm.nih.gov/pubmed/22308157 http://dx.doi.org/10.5812/kowsar.1735143X.733 |
_version_ | 1782222442977034240 |
---|---|
author | Aghemo, Alessio Rumi, Maria Grazia Monico, Sara Banderali, Matteo Russo, Antonio Ottaviani, Francesco Vigano, Mauro D’Ambrosio, Roberta Colombo, Massimo |
author_facet | Aghemo, Alessio Rumi, Maria Grazia Monico, Sara Banderali, Matteo Russo, Antonio Ottaviani, Francesco Vigano, Mauro D’Ambrosio, Roberta Colombo, Massimo |
author_sort | Aghemo, Alessio |
collection | PubMed |
description | BACKGROUND: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. OBJECTIVES: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. PATIENTS AND METHODS: Thirty-one naïve patients with chronic hepatitis C consecutively received PegIFN-α2a (180 μg/week) plus Rbv (800–1200 mg/day). The controls were 10 patients with chronic hepatitis B who received PegIFN-α2a (180 μg/week). During treatment and follow-up, all patients underwent basal and masticatory stimulated sialometry,otorhinolaryngoiatric (ORL) examination, and a questionnaire survey to subjectively assess symptoms of oral dryness. RESULTS: Twenty-seven patients on PegIFN/Rbv and 4 on PegIFN (87% vs. 40%, P = 0.006) reported xerostomia. Thirty patients on PegIFN/Rbv combination therapy and 2 patients on monotherapy had ORL signs of salivary gland hypofunction (97% vs. 20%, P < 0.0001).Mean basal (A) and stimulated (B) salivary flow rates (mL/min) progressively decreased during PegIFN/Rbv treatment (A, 0.49 at baseline vs. 0.17 at the end of treatment, P < 0.0001; B, 1.24 at baseline vs. 0.53 at the end of treatment, P = 0.0004). At week 24 following PegIFN/Rbv treatment, salivary flow rates were similar to baseline (A, 0.53 at the end of follow-up vs. 0.49 at baseline; B, 1.19 at the end of follow-up vs. 1.24 at baseline). Salivary function was unaffected in monotherapy patients. CONCLUSIONS: Rbv causes salivary gland hypofunction in hepatitis C patients receiving PegIFN/Rbv therapy, which promptly reverts to normal upon cessation of treatment. |
format | Online Article Text |
id | pubmed-3269061 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Kowsar |
record_format | MEDLINE/PubMed |
spelling | pubmed-32690612012-02-03 Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients Aghemo, Alessio Rumi, Maria Grazia Monico, Sara Banderali, Matteo Russo, Antonio Ottaviani, Francesco Vigano, Mauro D’Ambrosio, Roberta Colombo, Massimo Hepat Mon Brief Report BACKGROUND: Xerostomia is a common adverse event of unknown etiology observed during pegylated interferon (PegIFN)/Ribavirin (Rbv) treatment. OBJECTIVES: To assess the frequency and mechanisms of xerostomia during PegIFN/Rbv therapy. PATIENTS AND METHODS: Thirty-one naïve patients with chronic hepatitis C consecutively received PegIFN-α2a (180 μg/week) plus Rbv (800–1200 mg/day). The controls were 10 patients with chronic hepatitis B who received PegIFN-α2a (180 μg/week). During treatment and follow-up, all patients underwent basal and masticatory stimulated sialometry,otorhinolaryngoiatric (ORL) examination, and a questionnaire survey to subjectively assess symptoms of oral dryness. RESULTS: Twenty-seven patients on PegIFN/Rbv and 4 on PegIFN (87% vs. 40%, P = 0.006) reported xerostomia. Thirty patients on PegIFN/Rbv combination therapy and 2 patients on monotherapy had ORL signs of salivary gland hypofunction (97% vs. 20%, P < 0.0001).Mean basal (A) and stimulated (B) salivary flow rates (mL/min) progressively decreased during PegIFN/Rbv treatment (A, 0.49 at baseline vs. 0.17 at the end of treatment, P < 0.0001; B, 1.24 at baseline vs. 0.53 at the end of treatment, P = 0.0004). At week 24 following PegIFN/Rbv treatment, salivary flow rates were similar to baseline (A, 0.53 at the end of follow-up vs. 0.49 at baseline; B, 1.19 at the end of follow-up vs. 1.24 at baseline). Salivary function was unaffected in monotherapy patients. CONCLUSIONS: Rbv causes salivary gland hypofunction in hepatitis C patients receiving PegIFN/Rbv therapy, which promptly reverts to normal upon cessation of treatment. Kowsar 2011-11 2011-11-30 /pmc/articles/PMC3269061/ /pubmed/22308157 http://dx.doi.org/10.5812/kowsar.1735143X.733 Text en Copyright © 2011, Kowsar M.P. Co. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Report Aghemo, Alessio Rumi, Maria Grazia Monico, Sara Banderali, Matteo Russo, Antonio Ottaviani, Francesco Vigano, Mauro D’Ambrosio, Roberta Colombo, Massimo Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients |
title | Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients |
title_full | Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients |
title_fullStr | Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients |
title_full_unstemmed | Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients |
title_short | Ribavirin Impairs Salivary gland function During Combination Treatment With Pegylated Interferon Alfa-2a In HEpatitis C patients |
title_sort | ribavirin impairs salivary gland function during combination treatment with pegylated interferon alfa-2a in hepatitis c patients |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269061/ https://www.ncbi.nlm.nih.gov/pubmed/22308157 http://dx.doi.org/10.5812/kowsar.1735143X.733 |
work_keys_str_mv | AT aghemoalessio ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients AT rumimariagrazia ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients AT monicosara ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients AT banderalimatteo ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients AT russoantonio ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients AT ottavianifrancesco ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients AT viganomauro ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients AT dambrosioroberta ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients AT colombomassimo ribavirinimpairssalivaryglandfunctionduringcombinationtreatmentwithpegylatedinterferonalfa2ainhepatitiscpatients |